RevolutionLogo.png
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 08, 2021 16:01 ET | Revolution Medicines, Inc.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $300 Million REDWOOD CITY, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the...
RevolutionLogo.png
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
February 03, 2021 23:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock...
RevolutionLogo.png
Revolution Medicines Announces Proposed Public Offering of Common Stock
February 01, 2021 16:01 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common...
RevolutionLogo.png
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Blue-Star-Logo-1024x321.png
Blue Star Foods Corp. Signs Term Sheet to Acquire Taste of BC Aquafarms, Inc.
December 28, 2020 09:42 ET | Blue Star Foods Corp.
Acquisition Would Signify a Strategic Investment into the Recirculating Aquaculture Systems (RAS) Industry Miami, Florida, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (OTC: BSFC)...
RevolutionLogo.png
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
November 12, 2020 07:30 ET | Revolution Medicines, Inc.
Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination First-in-Class RAS(ON) Inhibitor Programs for Five Targets...
RevolutionLogo.png
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
October 24, 2020 09:45 ET | Revolution Medicines, Inc.
Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and...
RevolutionLogo.png
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
October 12, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
September 16, 2020 09:00 ET | Revolution Medicines, Inc.
Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON) REDWOOD CITY, Calif., Sept. 16,...
RevolutionLogo.png
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
September 08, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...